General Information
Mineralys HTN 202
A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy And Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on A Standardized Medication Regimen.
| Protocol | MLS-101-202 |
|---|---|
| Identifier | |
| UID | 024ac47b-0d26-4a00-ac76-7c88abfe6358 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Hypertension / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2022-05-24 17:32 |
| Last Updated | 2024-07-18 17:47 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2023-11-20 | No |
| Enrollment Open | 2023-07-10 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-06-15 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-06-26 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Mineralys Therapeutics |
|---|---|
| Division | Mineralys Therapeutics |
| Team | Mineralys Therapeutics |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Clinipace, Inc |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
